Mukka Proteins Approves Fund Raising Via NCDs Worth ₹75 Crore
Mukka Proteins Limited's Board approved raising funds via Non-Convertible Debentures (NCDs). The company will issue NCDs worth up to ₹25 crore through EBP and an additional ₹50 crore in one or more tranches. The meeting was held on May 15, 2026.
The fundraising through NCDs indicates a strategic move by the company to secure capital, which could impact its financial structure and future growth plans.
The company is raising funds through debt instruments, which can be seen as a positive step for business expansion or operational needs.
Mukka Proteins Limited announced on May 15, 2026, that its Board of Directors has approved a proposal to raise funds through the issuance of secured, rated, redeemable, non-convertible debentures (NCDs).
The company plans to raise up to ₹25 crore (Rupees Twenty-Five Crores only) through the issuance of certain secured, rated, listed, redeemable, non-convertible debentures on a private placement basis via an Electronic Bidding Platform (EBP).
Additionally, the Board has approved the issuance of further secured, rated, listed, non-convertible debentures aggregating up to ₹50 crore (Rupees Fifty Crores only) on a private placement basis, which can be issued in one or more tranches or series over time, either through EBP or non-EBP.
The meeting of the Board of Directors commenced at 3:20 p.m. and concluded at 3:55 p.m. on May 15, 2026.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.